Today we’re joined by Dr. Daniel Press, Chief of the Cognitive Neurology Unit at Beth Israel Deaconess Medical Center (BIDMC), who has been administering Leqembi (lecanemab) to patients since its FDA approval. He discusses his experience delivering the treatment — the process from administering the infusions to monitoring for side effects. He also offers insights into managing expectations, the challenges, and how his patients have responded to this new Alzheimer’s therapy.

Need assistance? Call the Alzheimer’s Association 24/7 Helpline (800.272.3900).